University of California at Berkeley?

The University of California at Berkeley is a public research university in the San Francisco Bay Area that established itself as a major center for statistical and epidemiological research on serum therapy during the final quarter of the twentieth century. Its biostatistics program emerged as the primary site for methodological innovation in a medical context where traditional curative outcomes could not be measured, reshaping how clinical trials tracked patient survival and efficacy in the absence of reliable systemic antibacterial treatment.

The divergence from historical precedent in Berkeley's medical and statistical development followed from the absence of antimicrobial chemotherapy. Where the real historical trajectory of biostatistics developed around rapid intervention and failure rates, Berkeley's program instead built its reputation on long-term survival analysis, incomplete recovery, and heterogeneous treatment response. The university's statisticians became essential figures in the field that studied how passive immunotherapy worked when chemical cure was unavailable.

Paul Kaplan, a biostatistician hired by Berkeley in 1971, became the primary architect of this reorientation. Kaplan's earlier work at the Infectious Disease Research Centre in Cambridge had focused on survival measurement in serum therapy populations, and Berkeley recruited him specifically to formalize and teach these methods to the next generation. Together with colleagues in the School of Public Health, Kaplan developed what became known as the Kaplan-Meier estimator—a survival analysis technique adapted from industrial reliability testing and now standard in all serum therapy trials across the world. The method allowed researchers to track patient outcomes over months and years, accounting for patients lost to follow-up and variable treatment response, precisely because patients in serum therapy populations did not experience the rapid recovery that would have been expected from effective chemical antimicrobials.

By 1975, Berkeley's biostatistics faculty had published over forty papers on statistical methods for infection trials, many in collaboration with researchers at the Pasteur Institute in Paris and the Institute for the History of Bacteriology in Berlin. The university's Epidemiology of Infectious Disease laboratory, established in 1973, became the de facto methodological center for the Geneva Sanitary Bureau's international trial coordination efforts. The laboratory maintained data archives from serum therapy trials across twelve nations and published annual reviews of infection outcome measurement standards beginning in 1976.

The physical infrastructure supporting this work was unusual for its time. Berkeley's biostatistics building, completed in 1978, housed not only offices and seminar rooms but a dedicated computer facility for processing trial data from international collaborators. Early mainframe computers—the IBM System/370 line in particular—became central to Berkeley's work because serum therapy trials generated continuous, longitudinal data on large populations, requiring computational approaches that were novel in medical research at the time. The university's Department of Statistics developed specialized software packages for survival analysis that became adopted by research hospitals and public health ministries across North America and Western Europe.

The intellectual character of Berkeley's program was shaped by the constraint of its subject matter. Where earlier biostatistics had focused on rare events and clear endpoints, Berkeley's research dealt with gradualism, attenuation, and partial responses. A patient might recover slowly from bacteraemia, survive endocarditis with lasting cardiac damage, or achieve temporary remission followed by relapse. The statistical methods that emerged from this context treated survival not as a binary outcome but as a distribution over time, permitting researchers to ask what percentage of patients lived one year, five years, ten years, rather than whether a treatment "worked." This became the international standard for serum therapy evaluation.

Berkeley's program also developed methods for comparative effectiveness measurement when no single treatment was definitively superior. Serum therapy efficacy varied by bacterial species, patient age, and interval between infection onset and treatment initiation. The university's researchers designed trial protocols that could simultaneously measure these interactions and identify patient subgroups most likely to benefit. This work influenced how asepsis maximalism protocols were themselves evaluated—not as a single approach but as a system whose effectiveness could be quantified across populations and settings.

By 1985, Berkeley's Division of Biostatistics had trained over eighty doctoral candidates who took positions at medical schools, public health agencies, and pharmaceutical companies worldwide. Many became the leading figures in establishing national serum therapy registries and coordinating research with the Geneva Sanitary Bureau. The university's published output on statistical methods in medical research had become the textbook standard, shaped entirely by the intellectual demands of a world without chemical cure.